Analysts See $-0.11 EPS for Galectin Therapeutics, Inc. (GALT)

March 15, 2018 - By Richard Conner

 Analysts See $ 0.11 EPS for Galectin Therapeutics, Inc. (GALT)
Investors sentiment decreased to 0.67 in Q3 2017. Its down 1.22, from 1.89 in 2017Q2. It dropped, as 7 investors sold Galectin Therapeutics, Inc. shares while 8 reduced holdings. 4 funds opened positions while 6 raised stakes. 3.22 million shares or 4.39% less from 3.37 million shares in 2017Q2 were reported.
Stratos Wealth Ltd stated it has 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Norris Perne French Ltd Liability Partnership Mi owns 30,500 shares. Goldman Sachs Group invested in 14,049 shares. Northern Trust Corp accumulated 0% or 80,739 shares. Moreover, Thrivent For Lutherans has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Benchmark Cap reported 0.32% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Dynamic Solutions Limited Liability has 10,000 shares. Vanguard Grp has invested 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Guggenheim Capital Limited Co has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Geode Cap Limited Co owns 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 195,411 shares. Royal Bankshares Of Canada has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 26 shares. Susquehanna Interest Grp Incorporated Limited Liability Partnership holds 168,648 shares or 0% of its portfolio. Morgan Stanley has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Deutsche Bankshares Ag holds 2 shares. 1,000 were reported by Riggs Asset Managment Inc.

Since January 25, 2018, it had 2 buys, and 2 sales for $2.64 million activity. The insider 10X Fund – L.P. sold 244,444 shares worth $1.33M. $1.33M worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) shares were sold by CZIRR JAMES C.

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.11 EPS on March, 29 before the open.They anticipate $0.02 EPS change or 15.38 % from last quarter’s $-0.13 EPS. After having $-0.13 EPS previously, Galectin Therapeutics, Inc.’s analysts see -15.38 % EPS growth. The stock decreased 8.29% or $0.43 during the last trading session, reaching $4.76. About 376,023 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 62.09% since March 15, 2017 and is uptrending. It has outperformed by 45.39% the S&P500.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Ratings Coverage

Among 5 analysts covering Galectin Therapeutics (NASDAQ:GALT), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Galectin Therapeutics had 12 analyst reports since September 21, 2015 according to SRatingsIntel. H.C. Wainwright downgraded the shares of GALT in report on Thursday, September 29 to “Neutral” rating. The rating was maintained by Roth Capital on Thursday, January 4 with “Buy”. The stock has “Sell” rating by TH Capital on Wednesday, September 28. The company was maintained on Wednesday, June 14 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, March 30 by H.C. Wainwright. The firm has “Mkt Perform” rating by FBR Capital given on Monday, October 3. The firm has “Buy” rating by H.C. Wainwright given on Monday, March 28. The rating was maintained by Roth Capital with “Buy” on Thursday, December 7. The stock has “Buy” rating by H.C. Wainwright on Monday, September 21. The stock has “Sell” rating by Roth Capital on Wednesday, September 28.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $172.02 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “Update On Galectin Therapeutics’ Potential Entry Into Cancer Market” on February 15, 2018, also with their article: “Galectin Therapeutics Reports 2017 Third Quarter Financial Results and …” published on November 07, 2017, published: “Galectin Therapeutics to Present at Two International Conferences in March” on March 09, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: and their article: “Galectin Therapeutics Is On To Something Big” published on January 07, 2018 as well as‘s news article titled: “Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting …” with publication date: March 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.